Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3124074 | 0.87 | DRD2 (0.45) | DRD2SLC6A3SLC6A4CCR1OPRM1 | |
| SCHEMBL3111224 | 0.87 | DRD2 (0.40) | DRD2SLC6A4CCR3SLC6A2ALDH1A1 | |
| SCHEMBL3111241 | 0.85 | DRD2 (0.49) | DRD2SLC6A3SLC6A4CCR3CCR1 | |
| SCHEMBL3121532 | 0.83 | DRD2 (0.50) | DRD2SLC6A3SLC6A4CCR3CCR1 | |
| SCHEMBL3119484 | 0.81 | DRD2 (0.54) | DRD2CCR3CCR1 | |
| SCHEMBL3119765 | 0.80 | DRD2 (0.47) | DRD2SLC6A3SLC6A4CCR1SLC6A2 | |
| SCHEMBL3126014 | 0.79 | DRD2 (0.48) | DRD2CCR1OPRM1OPRL1 | |
| SCHEMBL3122675 | 0.79 | DRD2 (0.47) | DRD2SLC6A3SLC6A4CCR3CCR1 | |
| SCHEMBL3113242 | 0.78 | DRD2 (0.42) | DRD2CCR3CCR1OPRM1OPRL1 | |
| SCHEMBL3111862 | 0.77 | SLC6A3 (0.50) | DRD2SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155671-B1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2017-12-20 | — | — | EP | disclosed |
| US-8188301-B2 | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2012-05-29 | — | — | US | disclosed |
| US-20100179211-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB (DK) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179211-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | PNMT, DBH, SLC6A2 | DRD2 9/4885SLC6A3 6/4885SLC6A4 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.